On 12 May 2021, the Committee for Medicinal Products for Veterinary Use (CVMP) adopted a positive opinion1, recommending the granting of a marketing authorisation for the veterinary medicinal product Bonqat, an oral solution, intended for cats. The applicant for this veterinary medicinal product is Orion Corporation.
Bonqat is an antiepileptic medicinal product containing pregabalin (ATCvet code: QN03AX16) as active substance, which binds to the auxiliary subunit (alpha2-delta protein) of voltage-gated calcium channels in the central nervous system thereby reducing the release of various neurotransmitters (glutamate and monoaminergic neurotransmitters) and producing its anxiolytic effect.
The benefit of Bonqat is that it alleviates in cats the acute anxiety and fear associated with transportation and veterinary visits.
The most common side effects are signs of sedation (characterised by tiredness, difficulties in perception of the position and movement of the body, and problems with balance) and vomiting.
The full indication is: Alleviation of acute anxiety and fear associated with transportation and veterinary visits.
Detailed conditions for the use of this product are described in the summary of product characteristics (SPC) which will be published in the European public assessment report (EPAR) and will be available in all official European Union languages after the marketing authorisation has been granted by the European Commission.
The CVMP, on the basis of quality, safety and efficacy data submitted, considers that there is a favourable benefit-risk balance for Bonqat and therefore recommends the granting of the marketing authorisation.
1Applicants may appeal any CVMP opinion, provided they notify the European Medicines Agency in writing of their intention to appeal within 15 days of receipt of the opinion.
|Agency product number||
|International non-proprietary name (INN) or common name||
|Date opinion adopted||